

Bioorganic & Medicinal Chemistry Letters 8 (1998) 2443-2446

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

SOLID-PHASE SYNTHESIS OF POTENTIAL PROTEIN TYROSINE PHOSPHATASE INHIBITORS VIA THE UGI FOUR-COMPONENT CONDENSATION

Zhengong Li, Su Ling Yeo^a, Catherine J. Pallen and A. Ganesan* Institute of Molecular and Cell Biology, National University of Singapore, 30 Medical Drive, Singapore 117609 and ^aGene Singapore Pte. Ltd.

Received 27 March 1998; accepted 22 July 1998

Abstract: A library of 108 α,α -difluoromethylenephosphonic acids was prepared by Ugi four-component condensation using Rink-NH₂ resin, 4-[(diethoxyphosphinyl)difluoromethyl]benzoic acid, and a set of 18 aldehydes and 6 isonitriles. Following resin cleavage, the diethylphosphonate esters were hydrolyzed with trimethylsilyl bromide to yield the free acids which were assayed for inhibition of PTP α , PTP β and PTP ϵ . © 1998 Elsevier Science Ltd. All rights reserved.

Keywords: Solid phase synthesis; phosphonic acids and derivs; enzyme inhibitors

Tyrosine phosphorylation levels, controlled by the relative activity of protein tyrosine kinases (PTKs) and phosphatases¹ (PTPases), play an important role in various cellular events. The regulation of PTPase activity is believed to be of importance in conditions such as cancer, diabetes and microbial pathogenesis. One approach to PTPase inhibition is based on competitive substrate analogs in which phosphotyrosine (pTyr) is replaced by non-hydrolyzable mimetics such as phosphonates,² sulfonates,³ and malonates.⁴

Following a report by Cao *et al.*⁵ on a series of cinnamates (1, Figure 1) which were micromolar inhibitors of HePTP, we wished to examine a library of analogous phosphonates (2) against receptor-like PTPs. In 2, α , α -difluorination should improve potency over simple benzylphosphonates, as the fluorine atoms lower the phosphonate pK_{a2} as well as enable hydrogen bonding interactions.⁶ Besides potential PTPase inhibition, phosphonates 2 can also be screened for binding to pTyr recognition elements⁷ such as SH2 domains.⁸



Our library preparation utilized the same strategy as Cao *et al.*: solid-phase synthesis⁹ via an Ugi four component condensation.¹⁰ Rink-NH₂ resin served as an ammonia equivalent, while both aldehyde and isonitrile components were varied. The desired 4-[(diethoxyphosphinyl)difluoromethyl]benzoic acid $(3)^{11}$ was obtained in three steps from 4-iodobenzoic acid (Scheme 1). The key step in this sequence, coupling of the iodide with an organozinc reagent, closely followed a recent report.¹²

0960-894X/98/\$ - see front matter © 1998 Elsevier Science Ltd. All rights reserved. *PII:* S0960-894X(98)00408-9



Solid-phase Ugi reactions¹³ (Scheme 2) with 3 were successful with a variety of aliphatic and aromatic aldehydes, while three commercially available isonitriles did not give good yields: 1*H*-benzotriazol-1-ylmethyl isocyanide, 2-morpholinoethyl isocyanide, and toluene-4-sulfonylmethyl isocyanide. Attempted resin-bound hydrolysis of the phosphonate esters with trimethylsilyl bromide (TMSBr) was problematic, presumably due to the sensitivity of the Rink resin to acidic conditions. Instead, post-cleavage hydrolysis was performed in solution to give the free phosphonic acids (2). As the byproducts of the TMSBr hydrolysis are volatile, purification was effected by simple evaporation.



A library of 108 discrete diamides was prepared¹⁴ using a set (**Table 1**) of six isonitriles and eighteen aldehydes. The identity of all intermediate phosphonate esters **4** was checked by ¹H NMR. After TMSBr hydrolysis, 20 % of the library was sampled and characterized by ¹H NMR and MS, while product purity was determined by HPLC analysis. Although product yields are variable, purities are uniformly high, reflecting the advantage of multicomponent condensations as unreacted synthetic intermediates do not build up on the resin.

The phosphonic acids were screened at 100 μ M for inhibition of *p*-nitrophenyl phosphate hydrolysis by the intracellular catalytic domains of three receptor-like PTPs: PTP α , β , and ε . Three compounds, **2d**, **2w**, and **2x**, inhibited PTP ε by more than 50 %. The low hit rate and the selectivity of inhibition suggests that subtle differences may exist between the active sites of closely related PTPs. In general, the activity observed is lower than that of the cinnamates against non-receptor HePTP. This may be due to differences between receptor and non-receptor PTPs, or a more complex mechanism than phosphotyrosine mimicry by the cinnamates.

Acknowledgment. This work was funded by grants from the National Science and Technology Board of Singapore.



Table 1. Library Building Blocks, Yield and Purity of Representative Examples.

Yield (%) and Purity^b (%) of Phosphonic acids 2

Comp'd	R ₁	R ₂	Yield	Purity	Comp'd	R_1	R_2	Yield	Purity	
2a	Α	а	95	90	2n	К	а	50	84	
2ь	Α	e	29	89	20	L	f	77	48	
2c	В	c	59	97	2p	М	e	23	94	
2d	С	с	23	96	2q	N	d	46	97	
2e	D	d	17	74	2 r	0	b	13	79	
2 f	Е	b	27	85	2s	Р	а	49	95	
2g	F	b	17	74	2t	Q	b	59	83	
2h	F	f	10	88	2u	R	c	65	74	
2i	G	d	42	97	2v	J	a	55	87	
2j	н	c	68	97	2w	Ι	с	19	69	
2k	I	a	34	97	2x	J	с	29	73	
21	J	e	15	78	2y	Q	с	67	75	
2m	J	f	11	85						

^aThe esters were also hydrolyzed by TMSBr in the final products; ^bBased on HPLC analysis with UV detection at 210 nm.

References and Notes

- For recent reviews on PTPases, see: a) Neel, B. G.; Tonks, N. K.; *Curr. Opin. Cell Biol.* 1997, 9, 193-204. b) Neel, B. G. *Curr. Opin. Immunol.* 1997, 9, 405-420. c) Widlanski, T. S.; Myers, J. K.; Stec, B.; Holtz, K. M.; Kantrowitz, E. R. *Chem. Biol.* 1997, 4, 489-492.
- For recent examples, see: a) Akamatsu, M.; Roller, P. P.; Chen, L.; Zhang, Z.-Y.; Ye, B.; Burke, T. R. Bioorg. Med. Chem. 1997, 5, 157-163. b) Frechette, R. F.; Ackerman, C.; Beers, S.; Look, R.; Moore, J. Bioorg. Med. Chem. Lett. 1997, 7, 2169-2172. c) Beers, S. A.; Malloy, E. A.; Wu, W.; Wachter, M. P.; Gunnia, U.; Cavender, D.; Harris, C.; Davis, J.; Brosius, R.; Pellegrino-Gensey, J. L.; Siekierka, J. Bioorg. Med. Chem. 1997, 5, 2203-2211. d) Wang, Q.; Huang, Z.; Ramachandran, C.; Dinaut, A. N.; Taylor, S. D. Bioorg. Med. Chem. Lett. 1998, 8, 345-350.
- 3. Marseigne, I.; Roques, B. P. J. Org. Chem. 1988, 53, 3621-3624.
- 4. Burke, T. R.; Ye, B.; Akamatsu, M.; Ford, H.; Yan, X.; Kole, H. K.; Wolf, G.; Shoelson, S. E.; Roller, P. P. J. Med. Chem. **1996**, *39*, 1021-1027.
- a) Cao, X.; Moran, E. J.; Siev, D.; Lio, A.; Ohashi, C.; Mjalli, A. M. M. Bioorg. Med. Chem. Lett. 1995, 5, 2953-2958. b) Mjalli, A. M. M.; Cao, X.; Moran, E. J. PCT Int. Appl. WO 1997, 970894.
- 6. Chen, L.; Wu, L.; Otaka, A.; Smyth, M. S.; Roller, P. P.; Burke, T. R.; den Hertog, J.; Zhang, Z.-Y. Biochem. Biophys. Res. Commun. 1995, 216, 976-984.
- 7. For a review, see: Shoelson, S. E. Curr. Opin. Chem. Biol. 1997, 1, 227-234.
- For example, see: Charifson, P. S.; Shewchuk, L. M.; Rocque, W.; Hummel, C. W.; Jordan, S. R.; Mohr, C.; Pacofsky, G. J.; Peel, M. R.; Rodriguez, M.; Sternbach, D. D.; Consler, T. G. *Biochemistry* 1997, 36, 6283-6293.
- For recent reviews on solid-phase organic synthesis, see: a) Hermkens, P. H. H.; Ottenheijm, H. C. J.; Rees, D. C. *Tetrahedron* 1996, 52, 4527-4554. b) Hermkens, P. H. H.; Ottenheijm, H. C. J.; Rees, D. C. *Tetrahedron* 1997, 53, 5643-5678. c) Brown, R. *Contemp. Org. Synth.* 1997, 4, 216-237.
- For reviews, see: a) Gokel, G.; Lüdke, G.; Ugi, I. In *Isonitrile Chemistry*; Ugi, I., Ed.; Academic: New York, 1971; pp. 145-199. b) Ugi, I.; Lohberger, S.; Karl, R. In *Comprehensive Organic Synthesis*; Trost, B. M., Fleming, I., Eds.; Pergamon: New York, 1991; Vol 2, pp 1083-1109.
- 11. ¹H NMR (CDCl₃, 300 MHz) for **3**: δ 8.16 (d, 2H, J = 8.1 Hz), 7.72 (d, 2H, J = 8.1 Hz), 4.34-4.15 (m, 4H), 3.83 (br s, 1H, D₂O exchangeable), 1.34 (t, 6H, J = 7.0 Hz).
- 12. Yokomatsu, T.; Murano, T.; Suemune, K.; Shibuya, S. Tetrahedron 1997, 53, 815-822.
- For solid-phase Ugi reactions besides ref 5a, see: a) Tempest, P. A.; Brown, S. D.; Armstrong, R. W. Angew. Chem. Int. Ed. Engl. 1996, 35, 640-642. b) Strocker, A. M.; Keating, T. A.; Tempest, P. A.; Armstrong, R. W. Tetrahedron Lett. 1996, 37, 1149-1152. c) Sutherlin, D. P.; Stark, T. M.; Hughes, R.; Armstrong, R. W. J Org. Chem. 1996, 61, 8350-8354. d) Zhang, C.; Moran, E. J.; Woiwode, T. F.; Short, K. M.; Mjalli, A. M. M. Tetrahedron Lett. 1996, 37, 751-754. e) Mjalli, A. M. M.; Sarshar, S.; Baiga, T. J. Tetrahedron Lett. 1996, 37, 2943-2946. f) Short, K. M.; Ching, B. W.; Mjalli, A. M. M. Tetrahedron 1997, 53, 6653-6679. g) Obrecht, D.; Abrecht, C.; Grieder, A.; Villalgordo, J. M. Helv. Chim. Acta 1997, 80, 65-72.
- 14. Typical procedure: Aldehyde (0.4 mmol) and Rink-NH₂ resin (0.05 mmol) were agitated in CH₂Cl₂ (2 h, rt). Acid **3** (0.2 mmol) and isonitrile (0.2 mmol, both 0.5 M in MeOH) were added, and the resulting mixture was agitated (3 days, rt). The resin was filtered and washed (DMF, MeCN, CH₂Cl₂). A mixture of TFA/Et₃SiH/CH₂Cl₂ (10:5:85; 1 mL) was added and the resin agitated (30 min, rt), filtered, and rinsed with CH₂Cl₂. The filtrate was dried in vacuo, re-dissolved in anhydrous CH₂Cl₂ (1.0 mL), followed by addition of anisole (50 μL) and TMSBr (46 μL, 0.35 mmol). After 3 h, MeOH (1 mL) was added, and the mixture evaporated in vacuo to afford the final product. **2g:** ¹H NMR (CD₃OD, 300 MHz) δ 7.93 (d, 2H, *J* = 8.0 Hz), 7.69 (d, 2H, *J* = 8.0 Hz), 7.39 (d, 2H, *J* = 7.2 Hz), 7.20 (d, 2H, *J* = 7.2 Hz), 5.60 (s, 1H), 2.33 (s, 3H), 1.32 (s, 9H); ¹³C NMR (CD₃OD, 100 MHz) δ 171.6, 168.4, 139.1, 138.0, 136.2, 130.3, 128.9, 128.6, 127.6, 127.5, 59.0, 52.3, 28.8, 21.1; MS (API) m/z, 453 (M⁺-1); **2y:** ¹H NMR (CD₃OD, 400 MHz): δ 8.74-8.52 (m, 1H), 8.11-7.98 (m, 1H), 7.92 (d, 2H, *J* = 8.0 Hz), 7.68 (d, 2H, *J* = 8.0 Hz), 7.64-7.48 (m, 1H), 7.32-7.03 (m, 6H), 5.67 (s, 1H), 4.52 (s, 2H); ¹³C NMR (CD₃OD, 100 MHz) δ 170.9, 168.6, 163.4, 149.5 139.0, 138.6, 138.5, 136.1 135.4, 131.6, 128.9, 128.2, 128.0, 127.5, 122.4, 120.7, 43.8; MS (API) *m/z*: 474 (M⁺-1).